AKYLA/ Financials
MarketsScreenerFinancialsResearchChat
Equity / PHARMACEUTICAL PREPARATIONS
Capricor Therapeutics Inc
XNAS · usd
SIC 2834 · PHARMACEUTICAL PREPARATIONS
FIGI BBG001SKJV12
5.93▼ 0.20 (-3.26%)
As of 2026-10-23
Price / Volume
Valuation
Market Cap
Enterprise Value
Trailing P/E
—
Price / Sales
—
EV / Revenue
—
EV / EBITDA
Financial Highlights
Revenue (TTM)
Net Income (TTM)
EBITDA
Diluted EPS (TTM)
EBITDA Margin
—
Net Debt
Trading Information
Previous Close
6.13
Day's Range
5.80 – 6.08
52-Week Range
2.96 – 40.37
Volume
1.4M
Avg Volume
3.3M
Share Statistics
Shares Outstanding
Employees
231
Exchange
XNAS
Listed
2002-06-20
Share count as of August 13, 2026

Capricor Therapeutics Inc (CAPR) Financial Statements

View
Income Statement
Detail
Standard
Period
Quarterly
Loading Income Statement…
Key questions about Capricor Therapeutics Inc (CAPR)
What is Capricor Therapeutics Inc's Market Cap?
Capricor Therapeutics Inc's Market Cap is $344.8M, based on as-reported figures from SEC (XBRL) filings.
What is Capricor Therapeutics Inc's Enterprise Value?
Capricor Therapeutics Inc's Enterprise Value is $323.8M, based on as-reported figures from SEC (XBRL) filings.
What is Capricor Therapeutics Inc's EV / EBITDA?
Capricor Therapeutics Inc's EV / EBITDA is n/m, based on as-reported figures from SEC (XBRL) filings.
What is Capricor Therapeutics Inc's Revenue (TTM)?
Capricor Therapeutics Inc's Revenue (TTM) is $0.00, based on as-reported figures from SEC (XBRL) filings.
What is Capricor Therapeutics Inc's Net Income (TTM)?
Capricor Therapeutics Inc's Net Income (TTM) is -$129.4M, based on as-reported figures from SEC (XBRL) filings.
What is Capricor Therapeutics Inc's EBITDA?
Capricor Therapeutics Inc's EBITDA is -$133.1M, based on as-reported figures from SEC (XBRL) filings.
What is Capricor Therapeutics Inc's Diluted EPS (TTM)?
Capricor Therapeutics Inc's Diluted EPS (TTM) is -2.23, based on as-reported figures from SEC (XBRL) filings.
What is Capricor Therapeutics Inc's Net Debt?
Capricor Therapeutics Inc's Net Debt is -$20.9M, based on as-reported figures from SEC (XBRL) filings.
Akyla / Financials · CAPRAs-filed SEC (XBRL) data
Showing the most recent year. Subscribe for full statement history.
Income Statement(in thousands of USD, except per-share data)
Source: Akyla.ai
Line ItemJun 30, 2026Mar 31, 2026Dec 31, 2025Sep 30, 2025Jun 30, 2025Mar 31, 2025Dec 31, 2024Sep 30, 2024Jun 30, 2024Mar 31, 2024Dec 31, 2023Sep 30, 2023Jun 30, 2023Mar 31, 2023Dec 31, 2022Sep 30, 2022
REVENUE
Revenue
TOTAL REVENUE————
YoY growth————
OPERATING EXPENSES
Research and development
General and administrative
TOTAL OPERATING EXPENSES
% of revenue————
LOSS FROM OPERATIONS
% of revenue————
OTHER INCOME (EXPENSE)
Other income (loss)
Investment income
TOTAL OTHER INCOME (EXPENSE)
LOSS BEFORE INCOME TAXES——
(Provision for) benefit from income taxes——
NET LOSS
% of revenue————
Net loss per share, basic (in dollars per share)
Net loss per share, diluted (in dollars per share)